Clinical Challenges And Innovations In Lung Cancer Management

Abstract

Lung cancer is the number one killer of the cancer court in the world today. Clinical challenges that surround the prognosis of lung cancer patients still challenge the strategies in therapy and diagnostic procedures though there have been improvements in the field of technology. Two most common histological subtypes, i.e., small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are central to these challenges. As such, the current synthesis has dealt with the leading clinical determinants of lung cancer outcomes: late-stage diagnosis, treatment resistance, limited access to personalized medications, and socioeconomic disparities. The current article also outlines modern approaches to therapy precision medicine, targeted therapy, immunotherapy, artificial intelligence (AI), and nanotechnology and transforming the healthcare industry. Future breakthroughs in management and testing are mentioned, with an emphasis on the recently recognized biomarkers and strategies of treatment that could enhance the survival of lung cancer patients. Finally, the ability to improve survival rates, optimality of treatment regimens, and the reduction of health disparities in lung cancer healthcare lies in the issue of systematically solving such clinical and technological challenges.